Literature DB >> 34912117

Synthon-based ligand discovery in virtual libraries of over 11 billion compounds.

Arman A Sadybekov1,2, Anastasiia V Sadybekov1,2, Yongfeng Liu3,4, Christos Iliopoulos-Tsoutsouvas5, Xi-Ping Huang3,4, Julie Pickett3,4, Blake Houser2, Nilkanth Patel1, Ngan K Tran5, Fei Tong5, Nikolai Zvonok5, Manish K Jain3, Olena Savych6, Dmytro S Radchenko6,7, Spyros P Nikas5, Nicos A Petasis2, Yurii S Moroz7,8, Bryan L Roth9,10,11, Alexandros Makriyannis12,13, Vsevolod Katritch14,15.   

Abstract

Structure-based virtual ligand screening is emerging as a key paradigm for early drug discovery owing to the availability of high-resolution target structures1-4 and ultra-large libraries of virtual compounds5,6. However, to keep pace with the rapid growth of virtual libraries, such as readily available for synthesis (REAL) combinatorial libraries7, new approaches to compound screening are needed8,9. Here we introduce a modular synthon-based approach-V-SYNTHES-to perform hierarchical structure-based screening of a REAL Space library of more than 11 billion compounds. V-SYNTHES first identifies the best scaffold-synthon combinations as seeds suitable for further growth, and then iteratively elaborates these seeds to select complete molecules with the best docking scores. This hierarchical combinatorial approach enables the rapid detection of the best-scoring compounds in the gigascale chemical space while performing docking of only a small fraction (<0.1%) of the library compounds. Chemical synthesis and experimental testing of novel cannabinoid antagonists predicted by V-SYNTHES demonstrated a 33% hit rate, including 14 submicromolar ligands, substantially improving over a standard virtual screening of the Enamine REAL diversity subset, which required approximately 100 times more computational resources. Synthesis of selected analogues of the best hits further improved potencies and affinities (best inhibitory constant (Ki) = 0.9 nM) and CB2/CB1 selectivity (50-200-fold). V-SYNTHES was also tested on a kinase target, ROCK1, further supporting its use for lead discovery. The approach is easily scalable for the rapid growth of combinatorial libraries and potentially adaptable to any docking algorithm.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34912117     DOI: 10.1038/s41586-021-04220-9

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  38 in total

Review 1.  Structure-based virtual ligand screening: recent success stories.

Authors:  Bruno O Villoutreix; Richard Eudes; Maria A Miteva
Journal:  Comb Chem High Throughput Screen       Date:  2009-12       Impact factor: 1.339

Review 2.  Cryo-EM in drug discovery: achievements, limitations and prospects.

Authors:  Jean-Paul Renaud; Ashwin Chari; Claudio Ciferri; Wen-Ti Liu; Hervé-William Rémigy; Holger Stark; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

Review 3.  Structure-function of the G protein-coupled receptor superfamily.

Authors:  Vsevolod Katritch; Vadim Cherezov; Raymond C Stevens
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-08       Impact factor: 13.820

Review 4.  Impact of GPCR Structures on Drug Discovery.

Authors:  Miles Congreve; Chris de Graaf; Nigel A Swain; Christopher G Tate
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

Review 5.  Structure-based drug screening for G-protein-coupled receptors.

Authors:  Brian K Shoichet; Brian K Kobilka
Journal:  Trends Pharmacol Sci       Date:  2012-04-13       Impact factor: 14.819

6.  Ultra-large library docking for discovering new chemotypes.

Authors:  Jiankun Lyu; Sheng Wang; Trent E Balius; Isha Singh; Anat Levit; Yurii S Moroz; Matthew J O'Meara; Tao Che; Enkhjargal Algaa; Kateryna Tolmachova; Andrey A Tolmachev; Brian K Shoichet; Bryan L Roth; John J Irwin
Journal:  Nature       Date:  2019-02-06       Impact factor: 49.962

7.  Accelerating high-throughput virtual screening through molecular pool-based active learning.

Authors:  David E Graff; Eugene I Shakhnovich; Connor W Coley
Journal:  Chem Sci       Date:  2021-04-29       Impact factor: 9.825

8.  Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.

Authors:  Reed M Stein; Hye Jin Kang; John D McCorvy; Grant C Glatfelter; Anthony J Jones; Tao Che; Samuel Slocum; Xi-Ping Huang; Olena Savych; Yurii S Moroz; Benjamin Stauch; Linda C Johansson; Vadim Cherezov; Terry Kenakin; John J Irwin; Brian K Shoichet; Bryan L Roth; Margarita L Dubocovich
Journal:  Nature       Date:  2020-02-10       Impact factor: 49.962

9.  Generating Multibillion Chemical Space of Readily Accessible Screening Compounds.

Authors:  Oleksandr O Grygorenko; Dmytro S Radchenko; Igor Dziuba; Alexander Chuprina; Kateryna E Gubina; Yurii S Moroz
Journal:  iScience       Date:  2020-10-15

10.  An open-source drug discovery platform enables ultra-large virtual screens.

Authors:  Andras Boeszoermenyi; Zi-Fu Wang; Christoph Gorgulla; Patrick D Fischer; Paul W Coote; Krishna M Padmanabha Das; Yehor S Malets; Dmytro S Radchenko; Yurii S Moroz; David A Scott; Konstantin Fackeldey; Moritz Hoffmann; Iryna Iavniuk; Gerhard Wagner; Haribabu Arthanari
Journal:  Nature       Date:  2020-03-09       Impact factor: 49.962

View more
  13 in total

1.  The Ukrainian Factor in Early-Stage Drug Discovery in the Context of Russian Invasion: The Case of Enamine Ltd.

Authors:  Ivan S Kondratov; Yurii S Moroz; Oleksandr O Grygorenko; Andrey A Tolmachev
Journal:  ACS Med Chem Lett       Date:  2022-06-10       Impact factor: 4.632

2.  Innovative chemistry yields potential antidepressant drugs.

Authors: 
Journal:  Nature       Date:  2022-09-28       Impact factor: 69.504

3.  Computational Cosolvent Mapping Analysis Leads to Identify Salicylic Acid Analogs as Weak Inhibitors of ST2 and IL33 Binding.

Authors:  Xinrui Yuan; Krishnapriya Chinnaswamy; Jeanne A Stuckey; Chao-Yie Yang
Journal:  J Phys Chem B       Date:  2022-03-16       Impact factor: 3.466

Review 4.  "Selective" serotonin 5-HT2A receptor antagonists.

Authors:  Austen B Casey; Meng Cui; Raymond G Booth; Clinton E Canal
Journal:  Biochem Pharmacol       Date:  2022-04-04       Impact factor: 6.100

Review 5.  GPCR systems pharmacology: a different perspective on the development of biased therapeutics.

Authors:  Dylan Scott Eiger; Uyen Pham; Julia Gardner; Chloe Hicks; Sudarshan Rajagopal
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-23       Impact factor: 5.282

6.  It all clicks together: In silico drug discovery becoming mainstream.

Authors:  Antonina L Nazarova; Vsevolod Katritch
Journal:  Clin Transl Med       Date:  2022-04

Review 7.  Assays Used for Discovering Small Molecule Inhibitors of YAP Activity in Cancers.

Authors:  Subhajit Maity; Artem Gridnev; Jyoti R Misra
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

Review 8.  Defining Levels of Automated Chemical Design.

Authors:  Brian Goldman; Steven Kearnes; Trevor Kramer; Patrick Riley; W Patrick Walters
Journal:  J Med Chem       Date:  2022-05-05       Impact factor: 8.039

Review 9.  Recent Advances in Structure, Function, and Pharmacology of Class A Lipid GPCRs: Opportunities and Challenges for Drug Discovery.

Authors:  R N V Krishna Deepak; Ravi Kumar Verma; Yossa Dwi Hartono; Wen Shan Yew; Hao Fan
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22

Review 10.  Next-Generation Molecular Discovery: From Bottom-Up In Vivo and In Vitro Approaches to In Silico Top-Down Approaches for Therapeutics Neogenesis.

Authors:  Sophie E Kenny; Fiach Antaw; Warwick J Locke; Christopher B Howard; Darren Korbie; Matt Trau
Journal:  Life (Basel)       Date:  2022-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.